ClinicalTrials.gov
public full text
Public Domain
A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis
This is a phase II study to determine the safety and preliminary efficacy of a human monoclonal antibody (BTT1023) which targets the vascular adhesion protein (VAP-1) and its use in the treatment of patients with primary sclerosing cholangitis (PSC).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- TRPV1 from the TRP family: Structure, function, implication in autoimmune diseases and potential therapies#4713
- MTS109 in Patients With Refractory Autoimmune Diseases#1060517
- Long-Term Follow-up of Adult With Atorpphic Scars Treated With TRTP-101#912710
- Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer#969792
- ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults#1072992
Record · ID 1138287
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive